Compare
Guided Therapeutics Inc vs iTonic Holdings Ltd vs Positron Corp vs Nexalin Technology, Inc.
| Latest fiscal year | Guided Therapeutics Inc GTHP | iTonic Holdings Ltd ITOC | Positron Corp POSC | Nexalin Technology, Inc. NXL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $767.0K | $523.0K | $461.5K | $301.6K |
| Revenue growth (YoY) | n/m | +16.7% | -21.5% | +78.8% |
| Gross margin | 74.4% | 62.6% | -458.2% | 79.7% |
| Operating margin | -309.3% | -991.7% | n/m | n/m |
| Net margin | -416.7% | -974.7% | n/m | n/m |
| Net income | -$3.20M | -$5.10M | -$10.60M | -$8.22M |
| EPS (Diluted) | -$0.04 | -$0.32 | -$0.34 | -$0.50 |
| Operating cash flow | -$1.07M | -$3.23M | -$4.70M | -$4.96M |
| Free cash flow | -$1.07M | -$3.24M | n/a | n/a |
| Cash & equivalents | n/a | $1.49M | n/a | $654.8K |
| Total assets | $1.32M | $9.10M | $4.00M | $4.64M |
| Total liabilities | $7.33M | $969.8K | $2.56M | $887.3K |
| Shareholders' equity | -$6.01M | $6.12M | $1.44M | $3.75M |
| Return on year-end equity | n/a | -83.3% | -734.4% | -219.4% |
| Shares outstanding | 86.15M | n/a | 32.80M | 19.19M |
Revenue, most recent five fiscal years
| Fiscal year | Guided Therapeutics Inc | iTonic Holdings Ltd | Positron Corp | Nexalin Technology, Inc. |
|---|---|---|---|---|
| Latest | $767.0K Ended 2025-12-31 | $523.0K Ended 2025-12-31 | $461.5K Ended 2025-12-31 | $301.6K Ended 2025-12-31 |
| 1 year earlier | $7.0K Ended 2024-12-31 | $448.2K Ended 2024-12-31 | $587.5K Ended 2024-12-31 | $168.7K Ended 2024-12-31 |
| 2 years earlier | $98.0K Ended 2023-12-31 | $628.6K Ended 2023-12-31 | n/a | $110.7K Ended 2023-12-31 |
| 3 years earlier | $13.0K Ended 2022-12-31 | $679.8K Ended 2022-12-31 | n/a | $1.32M Ended 2022-12-31 |
| 4 years earlier | $81.0K Ended 2021-12-31 | n/a | n/a | $144.1K Ended 2021-12-31 |